Is Kalydeco a brand name?
What is Kalydeco? Ivacaftor, known by its brand name Kalydeco, was the first precision medicine for cystic fibrosis to become available on the NHS in December 2016.
Is ivacaftor the same as Kalydeco?
Kalydeco (ivacaftor) is a treatment by Vertex Pharmaceuticals to treat cystic fibrosis caused by certain mutations. The therapy is approved in the U.S. and in Europe for patients, 4 months and older, with one of 97 genetic mutations.
What kind of drug is Kalydeco?
What is KALYDECO® (ivacaftor)? KALYDECO is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have at least one mutation in their CF gene that is responsive to KALYDECO. Talk to your doctor to learn if you have an indicated CF gene mutation.
What Kalydeco does to the body?
KALYDECO targets the underlying cause
In patients with a mutation in their CF gene that is responsive to KALYDECO, KALYDECO works to help the “gates” stay open longer, allowing more chloride ions to move into and out of the cells. The movement of chloride ions may help keep a balance of salt and water in the lungs.
Who manufactures Kalydeco?
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals.
How much does Kalydeco cost?
The cost for Kalydeco oral tablet 150 mg is around $26,405 for a supply of 56 tablets, depending on the pharmacy you visit.
…
Oral Tablet.
| Quantity | Per unit | Price |
|---|---|---|
| 56 | $471.52 | $26,405.09 |
Is Kalydeco a cure for CF?
Kalydeco® (ivacaftor) is approved to treat cystic fibrosis (CF) in people with one of 97 different kinds of CFTR mutations. It can be used by people with CF who are 4 months and older.
Who can take Kalydeco?
Check Your Eligibility
KALYDECO is for people with cystic fibrosis (CF) age 4 months and older with at least one mutation in their CF gene that is responsive to KALYDECO. Enter your mutations to see if at least one of them is eligible.
When was Kalydeco FDA approved?
Kalydeco was initially approved in 2012 for treatment of people ages 6 and older with the gating mutation G551D, who make up 4 percent of the 30,000 people with CF in the U.S. Last year, approval was expanded to babies ages 6 months and older with one of 38 mutations.
Why is KALYDECO so expensive?
The third rationale explaining the high prices for Kalydeco and Orkambi is fewer patients, which means high R&D costs per patient. On this basis, Vertex executives have made a case for the high price of the drugs (Nocera 2014; Verstraten 2014).
Who is eligible for KALYDECO?
KALYDECO is for people with cystic fibrosis (CF) age 4 months and older with at least one mutation in their CF gene that is responsive to KALYDECO. Enter your mutations to see if at least one of them is eligible.
Who is eligible for Kalydeco?
What is Kalydeco cystic fibrosis?
KALYDECO® (ivacaftor) is a precision medicine for the treatment of cystic fibrosis. It is a pill taken twice a day, with fat-containing food, that helps the protein made by the CFTR gene function better and, as a result, improves lung function and other aspects of cystic fibrosis such as increasing weight.
Is Ivacaftor FDA approved?
The U.S. Food and Drug Administration (FDA) has approved the use of ivacaftor (Kalydeco®) for babies with cystic fibrosis ages 6 to 12 months who have certain mutations. Ivacaftor is a CFTR modulator that increases activity of the CFTR protein at the cell surface and has been shown to improve lung function.
What is the cost of Kalydeco treatment for a year?
In response, Vertex, the manufacturer, priced Kalydeco in the US at about $300,000 per patient per year of treatment following its Food and Drug Administration (FDA) approval in 2012 (Silverman 2017).
How much does kalydeco cost?
Does Kalydeco cure cystic fibrosis?
The U.S. Food and Drug Administration today expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis. The approval triples the number of rare gene mutations that the drug can now treat, expanding the indication from the treatment of 10 mutations, to 33.
When was KALYDECO FDA approved?
How much does KALYDECO cost?
Why is kalydeco so expensive?